Clover Biopharmaceuticals, Ltd. is proud to announce an exclusive agreement with Adimmune Corporation that enables Clover to distribute AdimFlu-S (QIS) in mainland China, Bangladesh, Brazil and the Philippines. This is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and above, and is a major step forward in Clover’s mission to save lives and improve health through innovative vaccines around the world. Furthermore, the agreement opens the door for potential collaboration with Adimmune on the development of additional vaccine candidates, including next-generation influenza vaccines.
We are delighted to form a strategic partnership with Adimmune, a company with a proven reputation for providing critical vaccines to populations in Asia. This partnership puts Clover one step closer to establishing a leading respiratory vaccine franchise, and provides the opportunity to leverage the commercialization of our COVID-19 vaccine. The market for flu vaccines in general, and quadrivalent vaccines specifically, is expected to experience significant growth in mainland China.
Clover is thrilled to announce that it has secured commercial rights to AdimFlu-S (QIS) in mainland China, Bangladesh, Brazil and the Philippines. With a targeted commercial launch in H2 2023, Clover will be responsible for distributing AdimFlu-S (QIS) throughout mainland China, where the vaccine is already approved and where their existing commercial infrastructure and growing sales organization can be leveraged. Regulatory approval is pending for Bangladesh, Brazil and the Philippines, where Clover will also be commercializing AdimFlu-S (QIS). The vaccine is manufactured at Adimmune’s facility which has been certified for good manufacturing practices (GMP) by the European Medicines Agency and the U.S. Food and Drug Administration, among others.
Adimmune is delighted to join forces with Clover, an ever-growing commercial force in mainland China, renowned for its success in international collaborations. Together, we are committed to increasing seasonal influenza vaccinations, particularly for elderly people who are most vulnerable. Our high-quality quadrivalent vaccine will be key to achieving this goal.
Clover is proud to announce its strategic partnership with Adimmune, a move which marks a major step forward in establishing a leading respiratory franchise. With the launch of its COVID-19 vaccine in mainland China, and a growing and stable market for influenza vaccines, Clover’s collaboration with Adimmune is set to be a financial success, contributing to meaningful growth in 2024 and beyond.
Introducing AdimFlu-S (QIS): the quadrivalent split inactivated vaccine that promises to keep you safe from influenza! This powerful vaccine has the potential to achieve the highest vaccine effectiveness thanks to its inclusion of hemagglutinin from four different influenza virus strains (two A and two B). Approved by the China National Medical Products Administration in January 2022, AdimFlu-S (QIS) can be used by individuals aged three years and above. With this vaccine, you can be sure that you are doing all you can to stay safe from influenza!
About Clover Biopharmaceuticals
Clover Biopharmaceuticals is a pioneering biotechnology company that is committed to revolutionizing the healthcare landscape with innovative vaccines. Through its integrated research and development, manufacturing and commercial capabilities, as well as its extensive partnerships, Clover has a diverse and powerful range of potential candidates that can effectively reduce the burden of vaccine-preventable diseases and make many more diseases preventable. Together, Clover is on a mission to save lives and improve global health.